News
$Grifols(GRFS.US$ Grifols' Subsidiary Biotest Receives FDA Approval For Yimmugo, An Intravenous Immunoglobulin Therapeutic, To Treat Primary Immunodeficiencies, With US Launch Expected In Second Part Of 2024
Benzinga· 1 min ago
Benzinga· 1 min ago
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
TrytosaveabitOP : The Spanish pharmaceutical group said Monday it plans to launch the intravenous immunoglobulin therapeutic in the US within the year.